WCBA
BIIB icon

Weaver C. Barksdale & Associates’s Biogen BIIB Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-150
Closed -$46K – 548
2014
Q1 		$46K Hold
150
– – 0.04% 115
2013
Q4 		$42K Sell
150
-150
-50% -$38.8K 0.04% 131
2013
Q3 		$72K Hold
300
– – 0.07% 127
2013
Q2 		$65K Buy
+300
New +$64.1K 0.06% 118

Other funds holding BIIB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Weaver C. Barksdale & Associates's BIIB Position: Q2 2014 in Review

Weaver C. Barksdale & Associates sold out of Biogen (BIIB) in Q2 2014, closing a stake of 150 shares — an estimated $46K sold.

Weaver C. Barksdale & Associates first reported a position in BIIB in Q2 2013 and held it in 4 quarters. The position peaked at $72K in Q3 2013. 782 funds tracked by Wall St. Rank hold BIIB as of Q2 2014.

  • Weaver C. Barksdale & Associates reported no remaining Biogen position as of Q2 2014 after selling out during the quarter.
  • Weaver C. Barksdale & Associates sold 150 Biogen shares in Q2 2014, an estimated $46K.
  • Weaver C. Barksdale & Associates first reported a position in Biogen in Q2 2013 and held it in 4 quarters.
  • Weaver C. Barksdale & Associates's Biogen position peaked at $72K in Q3 2013.
  • 782 funds tracked by Wall St. Rank held Biogen as of Q2 2014.

Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2014, filed 11 Jul 2014.